Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From MorphoSys AG
Wugen has worked on its platform in stealth mode while co-founders at Washington University in St. Louis tested initial product WU-NK-101 in AML. Its new funding will support company-sponsored trials.
The subdued number of acquisitions of biotech by big pharma has more than one cause. The structural improvement of the process of drug discovery and development at big pharma is the main one.
The intellectual property, also held by Eureka, may offer a new pathway for treating relapsed MM patients. Sorrento inks cancer partnerships with Karolinska Institutet and Mayo Clinic.
Only 25 more initial public offerings are needed for 2021 to beat 2020’s record-breaking 86 IPOs. However, the average return for this year’s offerings is just 1.1% as of 1 July versus 11% at the end of the first quarter.
- Drug Discovery Tools
- Other Names / Subsidiaries
- Lanthio Pharma B.V.
- MorphoSys US Inc.
- Sloning BioTechnology
- Constellation Pharmaceuticals, Inc.